Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Hagberg

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Investigational New Drugs|November 11, 2015
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignanciesÅke Berglund, Anders Ullén, Alla Lisyanskaya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsTina Sarén, Mohanraj Ramachandran, Gustav Gammelgård, et al.
Medical Oncology (Northwood, London, England)|December 17, 2002
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trialAke Berglund, Bengt Glimelius, Jonas Bergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and LeukemiaGunilla Enblad, Hannah Karlsson, Gustav Gammelgård, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2018
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX)Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 28, 2005
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosisMattias Berglund, Ulf Thunberg, Rose-Marie Amini, et al.
Haematologica|November 11, 2003
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantationJohannes Schetelig, Sebastian Fetscher, Albrecht Reichle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2011
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximabBjörn Engelbrekt Wahlin, Christer Sundström, Harald Holte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01Francesco d'Amore, Thomas Relander, Grete F Lauritzsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|November 11, 2015
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignanciesÅke Berglund, Anders Ullén, Alla Lisyanskaya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsTina Sarén, Mohanraj Ramachandran, Gustav Gammelgård, et al.
Medical Oncology (Northwood, London, England)|December 17, 2002
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trialAke Berglund, Bengt Glimelius, Jonas Bergh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2018
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and LeukemiaGunilla Enblad, Hannah Karlsson, Gustav Gammelgård, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2018
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX)Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 28, 2005
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosisMattias Berglund, Ulf Thunberg, Rose-Marie Amini, et al.
Haematologica|November 11, 2003
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantationJohannes Schetelig, Sebastian Fetscher, Albrecht Reichle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2011
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximabBjörn Engelbrekt Wahlin, Christer Sundström, Harald Holte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01Francesco d'Amore, Thomas Relander, Grete F Lauritzsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphomaChristian Gisselbrecht, Norbert Schmitz, Nicolas Mounier, et al.
Pageof 5